martes, 17 de noviembre de 2026

Oncology News: LUGPA 2026 - Q&A: Why the Jury Is Still Out on Durvalumab for NMIBC (+...)

Oncology News LUGPA 2026 Q&A: Why the Jury Is Still Out on Durvalumab for NMIBC Despite a recent FDA approval, urologic oncologists are waiting for more data before embracing durvalumab add-on for patients with high-risk non-muscle invasive bladder cancer. Medscape Medical News, November 17, 2026 https://www.medscape.com/index/list_13474_0

Newer GLP-1 drugs to combat obesity may be the next global battleground over access to medicines, expert warns LSE professor Ken Shadlen argues drugmakers should ready licensing plans now

https://www.statnews.com/pharmalot/2026/11/16/semaglutide-obesity-glp1-access-medicines-low-income-countries/ By Ed SilvermanNov. 16, 2026 Pharmalot Columnist, Senior Writer Over the past few months, lower-cost generic versions of the blockbuster GLP-1 drug semaglutide, which is sold as Wegovy by Novo Nordisk for combating obesity, started to become available in some countries and will soon arrive in still others. Meanwhile, the pharmaceutical industry is racing to develop newer GLP-1 medicines that, to varying degrees, are forecast to be more effective, cause fewer side effects, and are easier to administer.

Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial The unexpected result is good news for patients with acute myeloid leukemia

https://www.statnews.com/2026/11/17/sellas-blood-cancer-immunotherapy-succeeds-clinical-trial/ By Adam FeuersteinNov. 17, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.

Obesity Week 2026 (+...)

https://www.medscape.com/c25/p14/obesity-week-2026-2026a100159b?ecd=wnl_conf_endo_obesity-week_SPON_261116_mscpedit_etid8908796&uac=148436CN&impID=8908796

American Society For Reproductive Medicine (ASRM) 2026 (+...)

https://www.medscape.com/c25/p14/american-society-reproductive-medicine-asrm-2026-2026a10010mu?ecd=wnl_conf_obgyn_ASRM_SPON_261116_mscpedit_clihub_etid8898607&uac=148436CN&impID=8898607

Bispecific ADCs could unlock thousands of new cancer targets A logic-gated platform is expanding what's druggable in antibody-drug conjugate development by pairing antigens that cancer cells co-express but normal tissue does not. Written byAndrea Corona

Bispecific ADCs could unlock thousands of new cancer targets A logic-gated platform is expanding what's druggable in antibody-drug conjugate development by pairing antigens that cancer cells co-express but normal tissue does not. Written byAndrea Corona https://www.drugdiscoverynews.com/bispecific-adcs-could-unlock-thousands-of-new-cancer-targets-17476?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8BeCXrQ-kYqh0UDGsFW7MsK5S6FQvFNM2yshB0EKBOjmiPy3resXW8MMGgE5U4hZMtrWJ9y-Kdj3UkCYCJSzwHoXlf2A&_hsmi=449562183&utm_content=449562183&utm_source=hs_email Antibody-drug conjugates have transformed oncology over the past decade, but they have been working with a limited playbook. The same small set of validated ADCs — including HER2, TROP2, NECTIN4, cMET and a few others — has anchored most ADC programs, not because researchers lack ambition, but because the biology of what makes a safe ADC target is genuinely constrained. Promatix Biosciences, a UK-based biotech, is attempting to expand that constraint using a proteomics-driven cis-bispecific discovery platform. By identifying pairs of antigens that are co-expressed on cancer cells but rarely co-expressed in normal tissue, the company aims to move ADC development from a field limited by target scarcity to one enriched with first-in-class target combinations to evaluate.

A new vulnerable window of time to prevent metastasis Researchers showed that before cancer cells metastasize the brain, they enter a “proliferative pause” that can be targeted with drugs to prevent metastasis altogether. Written byAllison Whitten, PhD

A new vulnerable window of time to prevent metastasis Researchers showed that before cancer cells metastasize the brain, they enter a “proliferative pause” that can be targeted with drugs to prevent metastasis altogether. Written byAllison Whitten, PhD https://www.drugdiscoverynews.com/a-new-vulnerable-window-of-time-to-prevent-metastasis-17576?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--5xJFKUe1c0pEgYx56iaabLCBR01JpR7Kzyeh3mEnyH2Pc8odWiuLU1ClsfE7K36DGfYgQ6UoIhVdJ9KbRlJMqPhEY8w&_hsmi=449562183&utm_content=449562183&utm_source=hs_email Cancer cells that migrate and attempt to metastasize a new organ do not receive a warm welcome. Instead, they must adapt to new conditions that often require changing their metabolism and reorganizing their DNA. The majority of them die. Those that survive create a new tumor, separate from the original, that must be eradicated through treatment as well. But some scientists are taking a different approach. “Why not, instead of treating established metastasis, try to prevent metastasis?” Manuel Valiente, a neuroscientist and brain cancer researcher at the Spanish National Cancer Research Centre, said to DDN. In a new paper published in Cancer Cell, Valiente’s team showed for the first time that there is a uniquely vulnerable time where prevention might be possible. “Unexpectedly, we have found that very aggressive cancer cells, metastatic cells that make it all the way to the brain, when they get in, they have to stop their aggressive nature for some time,” explained Valiente.